Medications

Patient Story

Ahmed was 68 years old when he was diagnosed with low-risk prostate cancer and placed on active surveillance. He had been taking finasteride for 12 years for an enlarged prostate and sildenafil occasionally for erectile dysfunction. His neighbor told him to stop all medications and start taking fenbendazole — a dog deworming pill — and curcumin capsules instead. "The doctors don't want you to know about these," his neighbor said. Ahmed's son found a viral video online about a man who claimed fenbendazole cured his cancer. Meanwhile, Ahmed's testosterone level came back low, and he wondered if testosterone replacement would be safe. Confused and anxious, Ahmed brought a list of questions to his next appointment. His urologist smiled and said, "I'm glad you asked. Let's go through each one together."

Part 1: 5-Alpha Reductase Inhibitors (Finasteride and Dutasteride)

What Are They?

Finasteride (Proscar, Propecia) and dutasteride (Avodart) belong to a class of drugs called 5-alpha reductase inhibitors (5-ARIs). They block the enzyme that converts testosterone into dihydrotestosterone (DHT) — a more potent form of testosterone that drives prostate growth. By reducing DHT, these drugs shrink the prostate and improve urinary symptoms.¹ ²

Finasteride blocks one type of the enzyme (type 2), while dutasteride blocks both types (types 1 and 2). Finasteride is also available at a lower dose (1 mg, brand name Propecia) for male pattern hair loss.¹

The Prevention Story

Two landmark trials tested whether 5-ARIs could prevent prostate cancer:

The Prostate Cancer Prevention Trial (PCPT): 18,882 men were randomized to finasteride 5 mg daily or placebo for 7 years. Finasteride reduced the overall risk of prostate cancer by 24.8%. However, a paradox emerged: more high-grade cancers (Gleason 7–10) were found in the finasteride group.³ ⁴

This paradox was later explained by detection bias — finasteride shrinks the prostate, making biopsies more accurate at finding cancers that were already there. In a smaller prostate, the biopsy needle samples a larger proportion of the gland, improving detection of both low-grade and high-grade cancers.³ ⁴

The REDUCE Trial: 8,231 men were randomized to dutasteride 0.5 mg daily or placebo for 4 years. Dutasteride reduced prostate cancer risk by 23%. A similar increase in high-grade cancers was observed, again likely due to detection bias.⁴

Long-Term Safety: Does Finasteride Increase Prostate Cancer Death?

This was the critical question. The answer, after decades of follow-up, is no.

• The 18-year follow-up of the PCPT showed no difference in overall survival or prostate cancer-specific mortality between finasteride and placebo groups.³
• A Swedish population-based study of over 348,000 men found no association between 5-ARI use and prostate cancer mortality (HR 0.86; 95% CI 0.78–0.95 — actually favoring 5-ARI users).⁵
• A meta-analysis of 5 studies (over 1.2 million men) confirmed no significant association between 5-ARI use and prostate cancer mortality (pooled HR 0.88; 95% CI 0.67–1.17).⁶
• A Canadian population-based study (2024) of over 80,000 men similarly found no increased prostate cancer mortality with 5-ARI use.⁷

Effect on PSA

5-ARIs reduce PSA by approximately 50% after 6–12 months of use. This is critical to understand: if you are on finasteride or dutasteride, your "true" PSA is roughly double the measured value. Any PSA increase while on a 5-ARI should be taken seriously and evaluated.¹ ²

Effect on MRI

A recent meta-analysis (2026) found that 5-ARI use does not compromise the accuracy of prostate MRI for detecting clinically significant cancer. PI-RADS scores and cancer detection rates were similar between 5-ARI users and non-users.⁸

The REDEEM Trial: Dutasteride on Active Surveillance

In the REDEEM trial, 302 men with low-risk prostate cancer on active surveillance were randomized to dutasteride or placebo for 3 years. Dutasteride reduced the risk of cancer progression by 38% and reduced the number of positive cores on repeat biopsy. However, it did not become standard practice because the long-term clinical significance of this finding remains uncertain.⁴

Side Effects

Common side effects of 5-ARIs include:¹ ²

• Erectile dysfunction (5–8%)
• Decreased libido (3–5%)
• Reduced ejaculate volume
• Gynecomastia (breast tenderness or enlargement, 1–3%)

These side effects are generally mild and often improve with continued use or after stopping the medication.

Psychiatric Concerns: Depression, Self-Harm, and Dementia

This topic has received significant attention:

Depression: A large Canadian cohort study found that 5-ARI use was associated with an increased risk of depression, particularly in the first 18 months (HR 1.94 for self-harm in the first 18 months). The absolute increase was small — approximately 237 additional cases per 100,000 patient-years.⁹

Self-harm: The same study found an increased risk of self-harm in the first 18 months of use (HR 1.88), but this risk diminished after 18 months and was not significant with longer use.⁹

Suicide: Multiple large studies have found no significant association between 5-ARI use and completed suicide.⁹ ¹⁰ ¹¹

Dementia: An initial association between 5-ARI use and dementia was observed, but a Swedish study of over 236,000 men showed this association diminished over 4 years of use, suggesting it was likely due to detection bias (men starting a new medication have more medical contact and are more likely to be diagnosed with pre-existing conditions).¹⁰ ¹¹

Finasteride vs. dutasteride: A 2025 pharmacovigilance analysis found that finasteride had a stronger signal for depression and suicidality than dutasteride, and younger men (18–44 years, typically using finasteride for hair loss) appeared to be at higher risk than older men using it for BPH.¹²

Bottom line: 5-ARIs are safe for most men, but mood should be monitored, especially in the first 18 months. Men with a history of depression should discuss this with their doctor before starting.

Post-Finasteride Syndrome (PFS)

Some men report persistent sexual, neurological, and psychological symptoms after stopping finasteride — a condition called post-finasteride syndrome (PFS). Symptoms include persistent erectile dysfunction, decreased libido, depression, anxiety, cognitive difficulties, and physical changes.¹³ ¹⁴

PFS is recognized by the European Medicines Agency and has been the subject of increasing research. However, it remains controversial:

• A study at a major academic center found that men reporting PFS had no evidence of androgen deficiency, decreased peripheral androgen action, or persistent enzyme inhibition — but they did show brain imaging (fMRI) findings consistent with depression.¹⁵
• The FDA added warnings about persistent sexual side effects to finasteride labeling in 2012.
• The condition appears to affect a small subset of men, possibly those with epigenetic susceptibility.¹³
• There are currently no evidence-based treatments for PFS. Current evidence does not support testosterone replacement for this condition.¹⁶

Practical advice: If you develop new sexual or mood symptoms while on finasteride or dutasteride, report them to your doctor. If symptoms persist after stopping the medication, seek evaluation from a urologist or endocrinologist.

If You Are Already on a 5-ARI When Diagnosed With Prostate Cancer

This is a common scenario. Whether to continue or stop depends on your treatment plan:

• If on active surveillance: continuing may be reasonable (REDEEM data suggests possible benefit)⁴
• If proceeding to surgery or radiation: discuss with your urologist/radiation oncologist
• Remember: PSA interpretation requires adjustment (multiply measured PSA by ~2)

📊 Illustration 13.1 — How 5-alpha reductase inhibitors work (testosterone → DHT pathway)

📊 Illustration 13.2 — The finasteride paradox explained visually

Part 2: PDE5 Inhibitors (Erectile Dysfunction Medications)

What Are They?

Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly prescribed medications for erectile dysfunction (ED). They work by increasing blood flow to the penis during sexual stimulation. They do not cause erections on their own — sexual arousal is still required.¹⁷ ¹⁸

Four PDE5 inhibitors are available:

All four have similar overall efficacy (~60–70% first-time response rate). The choice often depends on lifestyle preferences — tadalafil's long duration allows more spontaneity, while avanafil's rapid onset suits men who prefer on-demand use.¹⁷ ¹⁸ ¹⁹

Are PDE5 Inhibitors Safe in Prostate Cancer?

Yes. Multiple studies have confirmed that PDE5 inhibitors do not increase prostate cancer risk and do not increase the risk of cancer recurrence after treatment:

• The REDUCE trial analysis found no association between PDE5 inhibitor use and prostate cancer risk.²⁰
• A meta-analysis of studies examining PDE5 inhibitor use after prostate cancer treatment found no increased risk of biochemical recurrence.²¹
• A large Swedish population-based study (26,000+ men) found no association between PDE5 inhibitor use and disease recurrence after radical prostatectomy.²²
• One smaller study suggested a possible adverse effect on biochemical recurrence, but this was not confirmed by larger, better-designed studies.²¹ ²²
• At clinically relevant doses, PDE5 inhibitors do not directly affect prostate cancer cell behavior.²³

Emerging Signal: Could PDE5 Inhibitors Help Fight Cancer?

Intriguing but preliminary data suggest PDE5 inhibitors may have anticancer properties:

• A large database study (2025) of 108,630 matched patients found that PDE5 inhibitor use was associated with improved overall survival across male-predominant cancers (HR 0.42).²⁴
• The proposed mechanism involves immunomodulation — PDE5 inhibitors may reduce myeloid-derived suppressor cells and enhance T-cell antitumor responses.²⁵
• In laboratory studies, sildenafil potentiated the cancer-killing effects of docetaxel in prostate cancer models.²⁶

Important: These findings are hypothesis-generating, not practice-changing. PDE5 inhibitors should not be prescribed for cancer treatment outside of clinical trials. They are safe and effective for their intended purpose — treating erectile dysfunction.

Penile Rehabilitation

After prostate cancer treatment (surgery or radiation), early use of PDE5 inhibitors — sometimes called "penile rehabilitation" — may help preserve erectile tissue and improve long-term sexual function. This concept is discussed in more detail in Chapter 15 (Survivorship). Approximately 13% of long-term survivors after curative radiation use PDE5 inhibitors, with effectiveness depending on age, sexual interest, and overall health.²⁷

Contraindications and Cautions

• Absolute contraindication: Do not take PDE5 inhibitors with nitrates (nitroglycerin, isosorbide) — the combination can cause life-threatening low blood pressure.¹⁷
• Caution with alpha-blockers: If taking tamsulosin or other alpha-blockers for urinary symptoms, start PDE5 inhibitors at the lowest dose and separate timing. Tadalafil 5 mg daily is FDA-approved for both ED and BPH symptoms.¹⁷
• Cardiovascular clearance: Men who cannot tolerate moderate physical activity (equivalent to climbing two flights of stairs) should be evaluated by a cardiologist before starting PDE5 inhibitors.

📊 Illustration 13.3 — PDE5 inhibitor comparison table

Part 3: Testosterone Replacement Therapy (TRT)

The Historical Fear

For over 80 years, the medical community believed that testosterone "feeds" prostate cancer. This belief was based on the pioneering work of Charles Huggins in 1941, who showed that removing testosterone (castration) caused prostate cancer to regress, and adding testosterone caused it to grow.²⁸

This led to a deeply held — and overly simplified — belief: more testosterone = more cancer growth. As a result, testosterone replacement therapy was considered absolutely contraindicated in any man with a history of prostate cancer.

The Saturation Model: A New Understanding

In the early 2000s, Dr. Abraham Morgentaler proposed the saturation model, which fundamentally changed our understanding. The key insight: androgen receptors on prostate cancer cells become fully saturated at relatively low testosterone levels (approximately 230 ng/dL). Above this threshold, additional testosterone does not stimulate further cancer growth — the receptors are already fully occupied.²⁸ ²⁹

Think of it like watering a sponge: once the sponge is fully saturated, adding more water does not make it hold more. Similarly, once androgen receptors are saturated, raising testosterone from low-normal to high-normal does not accelerate cancer growth.

This model explains why:

• Men with low testosterone get prostate cancer at the same rate as men with high testosterone
• Testosterone replacement in hypogonadal men does not appear to increase prostate cancer risk
• The dramatic cancer response to castration occurs because testosterone drops below the saturation point

The SPIRIT Trial (2026): The First Randomized Trial

The SPIRIT trial was a landmark — the first randomized, placebo-controlled trial of testosterone replacement in prostate cancer survivors.³⁰

Study design:

• 136 men with low-grade prostate cancer (Gleason 6 or 3+4)
• All had undergone radical prostatectomy with undetectable PSA for ≥2 years
• All had confirmed hypogonadism (low testosterone with symptoms)
• Randomized to testosterone gel or placebo for 12 weeks

Results:

• TRT significantly improved sexual activity, sexual desire, well-being, body composition, and aerobic performance³⁰
• No biochemical recurrence occurred during treatment or 3-month follow-up³⁰
• No safety signals

Limitations: Short duration (12 weeks), small sample size, only low-grade cancers, only post-prostatectomy patients. This trial does not apply to men with high-grade cancer, metastatic disease, or those on ADT.

Other Evidence

• A retrospective study of men who received TRT after radiation therapy (with or without prior ADT) found low biochemical recurrence rates (weighted mean 3.3%) and improvements in fatigue, mood, and sexual symptoms.³¹
• A scoping review of 12 studies found that TRT was not associated with increased biochemical recurrence or cancer progression in any study.³²
• A systematic review of 19 observational studies supported cautious use of TRT in men with localized, low-to-intermediate risk disease after definitive treatment.³³
• The TRAVERSE trial (2023) — a large randomized trial of TRT in hypogonadal men without prostate cancer — found no increased risk of high-grade prostate cancer with TRT compared to placebo.³⁴

What Do the Guidelines Say?

The NCCN Survivorship Guidelines state that TRT is contraindicated in men with active or metastatic prostate cancer. For prostate cancer survivors, TRT remains controversial and should be coordinated with the treating oncologist.³⁵

How to Diagnose Hypogonadism Properly

Before considering TRT, hypogonadism must be properly diagnosed:

• Two morning testosterone levels (testosterone is highest in the morning and varies day to day)
• Both total and free testosterone should be measured
• Symptoms must be present: fatigue, low libido, erectile dysfunction, depressed mood, loss of muscle mass, increased body fat
• Other causes of low testosterone should be excluded (medications, pituitary disease, obesity, sleep apnea)

Types of TRT Delivery

Clomiphene Citrate: An Alternative for Younger Men

For younger men who want to preserve fertility, clomiphene citrate (off-label) stimulates the body's own testosterone production without suppressing sperm production. This is important because exogenous testosterone shuts down sperm production and can cause infertility.

Who May Be a Candidate for TRT After Prostate Cancer?

Based on current evidence, TRT may be considered in men who meet all of the following:³⁰ ³² ³³

• Low-grade cancer (Gleason 6 or 3+4)
• Definitive treatment completed (surgery or radiation)
• Undetectable or stable PSA for ≥2 years
• Confirmed hypogonadism with bothersome symptoms
• Shared decision-making with urologist and oncologist

Who Should NOT Receive TRT?

• Active or metastatic prostate cancer
• Currently on ADT
• High-grade disease (Gleason 4+3 or higher) — insufficient safety data
• Untreated prostate cancer (even low-grade, outside of clinical trials)

Monitoring on TRT

• PSA and testosterone levels every 3–6 months
• Digital rectal exam annually
• Hematocrit (TRT can increase red blood cell count)
• Any PSA rise → stop TRT and evaluate immediately

The Emotional Weight of This Topic

Many men feel their masculinity, energy, and identity are tied to testosterone. A diagnosis of prostate cancer — especially when combined with ADT — can feel like a double blow. The desire for TRT is often about much more than a number on a lab test. These feelings are valid and should be acknowledged by the medical team.

📊 Illustration 13.4 — The testosterone saturation model

📊 Illustration 13.5 — TRT decision guide flowchart

Part 4: Supplements — What Patients Ask About

A Note Before We Begin

We understand why patients seek supplements and alternative treatments. The desire to do everything possible is natural and valid. The goal of this section is not to dismiss your choices but to give you the facts so you can make truly informed decisions. The danger is not in asking questions — it is in replacing proven treatments with unproven ones.

Up to 87% of cancer patients use at least one form of complementary or alternative therapy after diagnosis.³⁶ Yet up to 77% do not tell their oncologist.³⁶ The most common reasons for not disclosing: fear of being judged, belief that supplements are irrelevant to cancer treatment, or simply not being asked.³⁶

Curcumin (Turmeric)

What it is: The active compound in turmeric, a common spice.

Preclinical promise: Curcumin modulates multiple cancer-related pathways (PI3K/Akt/mTOR, NF-κB, androgen receptor signaling) and induces cancer cell death in laboratory studies. One small study of 97 patients showed PSA decline with 1,440 mg/day orally.³⁷

Major limitation: Extremely poor oral bioavailability — very little curcumin reaches the bloodstream after oral ingestion. Nanoformulations (such as Theracurmin) may improve absorption but have not been tested in large cancer trials.³⁷ ³⁸

Verdict: 🟢 Possibly beneficial as a supplement alongside standard treatment. Not a substitute for proven therapies. Generally safe at typical doses.

Green Tea Catechins (EGCG)

What it is: Epigallocatechin-3-gallate (EGCG) is the main polyphenol in green tea.

Evidence: A proof-of-principle trial gave 600 mg/day of green tea catechins to 30 men with high-grade prostatic intraepithelial neoplasia (HGPIN). After one year, only 1 man (3%) developed prostate cancer, compared to 9 of 30 (30%) in the placebo group.³⁹ A meta-analysis found that green tea catechins reduced prostate cancer risk (RR 0.38).⁴⁰ A 2025 meta-analysis of 43 studies confirmed that green tea and EGCG reduced overall cancer risk, with a particularly notable effect on prostate cancer (RR 0.43).⁴¹

Caution: High-dose EGCG supplements (>800 mg/day) have been associated with liver toxicity. Drinking green tea as a beverage (3–7 cups/day) is considered safe.⁴²

Verdict: 🟢 Reasonable as a beverage (3–5 cups/day). High-dose supplements should be used with caution and discussed with your doctor.

Modified Citrus Pectin (PectaSol-C)

What it is: A modified form of pectin (a fiber found in citrus fruit peels) that can be absorbed into the bloodstream.

Evidence: Laboratory studies show it inhibits proliferation and induces cancer cell death in both androgen-dependent and androgen-independent prostate cancer cell lines. The proposed mechanism involves inhibition of galectin-3, a protein involved in cancer cell adhesion and metastasis.⁴³ ⁴⁴

Limitation: No large clinical trials demonstrating cancer outcomes benefit in humans.

Verdict: 🟡 Early-stage evidence only. Not harmful, but unproven for cancer treatment.

Quercetin

What it is: A flavonoid found naturally in apples, onions, berries, and green tea.

Evidence: Preclinical studies show quercetin suppresses androgen receptor and PSA expression, induces cancer cell death, and works synergistically with curcumin.⁴⁵ ⁴⁶

Limitation: No clinical trials in prostate cancer patients.

Verdict: 🟡 Dietary intake through fruits and vegetables is reasonable and encouraged. Supplementation is unproven.

Zinc

What it is: An essential mineral. The prostate has the highest zinc concentration of any organ in the body.

The paradox: While zinc is important for normal prostate function, supplementation of more than 75 mg per day or for more than 15 years may substantially increase the risk of lethal and aggressive prostate cancer.⁴⁷

Verdict: 🟡 Moderate dietary intake is reasonable. High-dose, long-term supplementation should be avoided.

Lactoferrin

What it is: A natural glycoprotein found in milk with immunomodulatory properties.

Evidence: Laboratory studies show it inhibits prostate cancer cell migration and works synergistically with curcumin.⁴⁸

Limitation: No clinical trials in prostate cancer.

Verdict: 🟡 Early preclinical evidence only.

Saw Palmetto

What it is: An extract from the berry of the saw palmetto palm tree, widely used for BPH/urinary symptoms.

Evidence for BPH: Despite decades of use and early positive studies, rigorous randomized trials — including the STEP trial and a dose-escalation trial up to 960 mg/day (3 times the standard dose) — found saw palmetto was no more effective than placebo for urinary symptoms.⁴⁹ ⁵⁰

Evidence for prostate cancer: None. Saw palmetto has no demonstrated anticancer activity.

Important distinction from finasteride: Saw palmetto does not affect PSA levels. This means it will not mask a rising PSA.⁵¹

Verdict: 🟡 Safe but likely ineffective for BPH based on rigorous trials. No role in prostate cancer.

Vitamin D

What it is: A fat-soluble vitamin important for bone health, immune function, and many cellular processes.

Evidence: Low vitamin D levels have been associated with more aggressive prostate cancer in some observational studies. However, supplementation trials have not shown a clear cancer prevention or treatment benefit.⁴⁷

Verdict: 🟢 Supplementation to achieve normal levels (30–50 ng/mL) is reasonable, especially for men on ADT (who are at risk for bone loss). Mega-dosing is not supported.

Omega-3 Fatty Acids

What it is: Polyunsaturated fats found in fish, flaxseed, and walnuts.

Evidence: Conflicting data. Some studies suggest benefit, but a secondary analysis of the SELECT trial suggested possible increased prostate cancer risk at high supplemental doses.⁴⁷

Verdict: 🟡 Dietary intake through fish (2–3 servings per week) is preferred over high-dose supplements.

Vitamin E and Selenium

What they are: Antioxidant supplements once thought to prevent prostate cancer.

Evidence: The SELECT trial (35,533 men) found that vitamin E supplementation increased prostate cancer risk by 17%, and selenium showed no benefit. The combination of selenium and vitamin E also showed no benefit and a possible harmful effect.⁴⁷

Verdict: 🔴 Not recommended for prostate cancer prevention. The SELECT trial definitively answered this question.

📊 Illustration 13.6 — Supplement evidence pyramid

Part 5: Other Medications of Interest

NSAIDs (Aspirin, Ibuprofen)

Some epidemiological studies suggest that regular NSAID use may be associated with a modestly reduced risk of prostate cancer. However, the evidence is inconsistent, and the bleeding risks of long-term NSAID use outweigh any potential cancer prevention benefit. Not recommended solely for prostate cancer prevention.⁴⁷

Statins

Observational data suggest a possible reduced risk of advanced prostate cancer with statin use. The mechanism may involve cholesterol's role in androgen synthesis. However, no randomized trial has tested statins for prostate cancer prevention. Not recommended for cancer prevention, but if you are already taking a statin for cholesterol, there may be an added benefit.⁴⁷

Metformin

This diabetes medication has shown preclinical anticancer properties (inhibits mTOR pathway, reduces insulin and IGF-1 levels). Several clinical trials in prostate cancer are ongoing. Not recommended outside of clinical trials for cancer treatment, but safe to continue if prescribed for diabetes.

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)

These increasingly prescribed medications for obesity and diabetes are relevant to prostate cancer patients for two reasons:

1. Emerging cancer data: Early epidemiological studies suggest possible reduced cancer risk with GLP-1 agonist use, but this is preliminary and not a reason to prescribe them for cancer.
2. Practical importance: GLP-1 agonists must be stopped before procedures requiring anesthesia (including prostate biopsies under general anesthesia) due to the risk of aspiration from delayed gastric emptying. Follow your anesthesiologist's instructions about when to stop.

Opioids and Testosterone

Chronic opioid use (for pain management) suppresses testosterone production — a condition called opioid-induced hypogonadism. This is relevant for men with prostate cancer who are on long-term pain medications, as it can worsen fatigue, depression, and sexual dysfunction beyond what the cancer or its treatment causes. If you are on chronic opioids and experiencing these symptoms, discuss testosterone testing with your doctor.

📊 Illustration 13.7 — "Tell Your Doctor" checklist

Part 6: The Conversation About Supplements With Your Doctor

Why Patients Don't Tell Their Doctors

• Fear of being judged or dismissed
• Belief that "natural" products are irrelevant to cancer treatment
• Assumption that supplements cannot interact with medications
• The doctor did not ask

Why Your Doctor Needs to Know

Drug interactions are real and can be dangerous:

• Curcumin affects CYP enzymes and may alter the metabolism of cancer drugs
• Green tea in high doses can interfere with certain chemotherapy agents (bortezomib)
• St. John's wort reduces the effectiveness of many medications, including some cancer drugs
• High-dose antioxidants (vitamin C, vitamin E) may theoretically reduce the effectiveness of radiation therapy and some chemotherapy drugs by protecting cancer cells from oxidative damage

How to Have the Conversation

1. Bring a written list of everything you take — prescription medications, over-the-counter drugs, vitamins, supplements, herbal products, and anything else
2. Be honest — your doctor is not there to judge you
3. Ask specifically: "Can any of these interact with my cancer treatment?"
4. Ask about integrative oncology programs — many major cancer centers now have dedicated integrative medicine teams that can help you navigate supplements safely

Part 7: Alternative and Unproven Cancer Treatments — What You Need to Know

Why This Section Matters

A large cohort study of over 2.1 million women with breast cancer found that those who used complementary and alternative medicine (CAM) instead of traditional therapies had dramatically worse survival — similar to receiving no treatment at all (adjusted HR 3.67 for CAM alone vs. traditional therapy). Even combining CAM with traditional therapy was associated with higher mortality (adjusted HR 1.45), largely because patients in the combination group were more likely to refuse recommended treatments such as radiation, chemotherapy, and endocrine therapy.⁵²

A separate study found that patients who chose alternative medicine as their sole cancer treatment had a 2.5-fold increased risk of death compared to those receiving conventional treatment, with the risk being even higher for breast cancer (HR 5.68) and colorectal cancer (HR 4.57).⁵³

The mortality risk was mediated by refusal of conventional treatment — when patients used complementary therapies alongside standard treatment without refusing any recommended therapy, the survival difference largely disappeared.⁵⁴

The message is clear: complementary therapies used alongside standard treatment are generally safe. Alternative therapies used instead of standard treatment can be deadly.

High-Dose Intravenous Vitamin C (IV Vitamin C)

What it is: Megadose vitamin C (15–100 grams) given intravenously — far exceeding what oral supplements can achieve. At these concentrations, vitamin C acts as a pro-oxidant, generating hydrogen peroxide that may selectively damage cancer cells.⁵⁵ ⁵⁶

History: Popularized by Nobel laureate Linus Pauling in the 1970s. Initial studies were flawed (used oral vitamin C, which cannot achieve pharmacologic blood levels). Interest has resurged with the understanding that IV and oral vitamin C have fundamentally different pharmacokinetics.⁵⁵

Clinical evidence: Early-phase trials have confirmed safety and suggested possible quality-of-life improvements (less fatigue, less nausea) when used alongside chemotherapy. Some studies in pancreatic and colorectal cancer suggest possible benefit in KRAS-mutated tumors. However, no Phase III trial has demonstrated a survival benefit in any cancer type, including prostate cancer.⁵⁵ ⁵⁶ ⁵

Risks: Generally well-tolerated, but important cautions exist:⁵⁵ ⁵⁶ ⁵⁷

• Must screen for G6PD deficiency before starting — patients with this genetic condition can develop severe hemolytic anemia (destruction of red blood cells) with high-dose vitamin C
• Can cause kidney stones and, rarely, kidney failure
• Can falsely elevate blood glucose readings on certain monitors
• May interfere with certain chemotherapy drugs and imaging tests
• Common mild side effects: nausea, lightheadedness, dry mouth
• Cost: typically $100–200 per infusion, 2–3 times per week, not covered by insurance

The VITALITY Trial (2022): The largest randomized trial of IV vitamin C in cancer was conducted in 442 patients with metastatic colorectal cancer. High-dose vitamin C (1.5 g/kg/day IV for 3 days) added to FOLFOX chemotherapy did not improve progression-free survival overall (8.6 vs. 8.3 months; HR 0.86; P = 0.1). However, in a prespecified subgroup analysis, patients with RAS mutations had significantly longer PFS with vitamin C (9.2 vs. 7.8 months; HR 0.67; P = 0.01).⁵⁸

Prostate cancer specifically: A Phase II trial of IV vitamin C combined with docetaxel in metastatic castration-resistant prostate cancer was initiated at Johns Hopkins, but no Phase III data demonstrating survival benefit in prostate cancer exist.⁵⁹

Verdict: 🟡 Not harmful as a complementary therapy alongside standard treatment in most patients (after G6PD screening). No evidence it treats prostate cancer. Should NOT replace proven therapies. Must inform oncologist due to potential drug interactions.

Mistletoe Therapy (Iscador, Helixor, Iscucin)

What it is: An extract from European mistletoe (Viscum album L.), given as subcutaneous injection. It is the most frequently prescribed complementary medicine for cancer patients in German-speaking countries.⁶⁰ ⁶¹

Prevalence: Widely used in Europe, particularly Germany, Switzerland, and Austria. Available as approved drugs in Germany (based on monographs of the German Federal Institute for Drugs and Medical Devices). In Switzerland, treatment costs are generally covered by statutory health insurance. In Germany, coverage is limited to palliative care.⁶⁰

Active compounds: Contains mistletoe lectins (ML-I, ML-II, ML-III), viscotoxins, flavonoids, amino acids, polysaccharides, and membrane lipids. Preclinical studies have demonstrated cytotoxic, apoptosis-inducing, and immunomodulatory effects.⁶⁰ ⁶¹ ⁶²

Clinical evidence:

• A Cochrane systematic review (2008) concluded: "There was not enough evidence to reach clear conclusions about the effects on any of these outcomes and it is therefore not clear to what extent the application of mistletoe extracts translates into improved symptom control, enhanced tumour response or prolonged survival."⁶³
• A systematic review (2019) of 28 publications with 2,639 patients found that most studies did not show any effect of mistletoe on survival. The authors concluded: "With respect to survival, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer."⁶⁴
• A meta-analysis of Iscador studies found a pooled hazard ratio of 0.59 (favoring mistletoe), but acknowledged significant publication bias and methodological limitations that limit the reliability of this finding.⁶⁵
• Some studies suggest improved quality of life (less fatigue, better appetite, fewer chemotherapy side effects), and these findings are evaluated more positively than survival data.⁶⁰
• A Phase II trial (MISTOSUS) is currently underway in the US testing Viscum album extract in relapsed osteosarcoma, based on a pilot study showing 55% post-relapse event-free survival in 9 patients.⁶⁶

Prostate cancer specifically: Very limited data. No randomized controlled trial has demonstrated tumor response or survival benefit in prostate cancer.

Risks: Injection site reactions (redness, swelling), fever, flu-like symptoms. Occasionally, pseudo-allergic reactions can occur. Otherwise generally safe, even at higher doses.⁶⁰

Regulatory status: Not FDA-approved in the US. Available in some integrative oncology clinics. Widely available in Europe.

Verdict: 🟡 May improve quality of life as a complementary therapy in some patients. No reliable evidence of anticancer effect in prostate cancer. Should not replace standard treatment.

Fenbendazole

What it is: A veterinary deworming drug (benzimidazole class) used in dogs, cats, and livestock. Not FDA-approved for human use.⁶⁷ ⁶⁸

How it became popular: A single viral story (Joe Tippens, 2019) claimed fenbendazole cured his lung cancer. The story spread on social media and has been viewed millions of times. The narrative has since expanded, with patients using fenbendazole for many cancer types.

Preclinical rationale: Fenbendazole destabilizes microtubules (similar mechanism to taxane chemotherapy), inhibits glucose uptake by downregulating GLUT transporters and hexokinase II, modulates p53, and impairs proteasomal function. It has shown cytotoxicity against various cancer cell lines in laboratory studies.⁶⁷ ⁶⁸ ⁶⁹

Critical problems:

1. No human clinical trials exist. Not a single Phase I, II, or III trial has been completed in any human cancer.⁶⁸ ⁷⁰
2. Human pharmacokinetics are poorly understood. Fenbendazole's absorption, metabolism, and safe dosing in humans have not been well-documented in medical literature.⁶⁸
3. The original viral story is misleading. The patient who popularized fenbendazole was also receiving conventional treatment (enrolled in a pembrolizumab clinical trial). Fenbendazole was not the only treatment he received.
4. Quality control concerns. Veterinary formulations are not manufactured to human pharmaceutical standards.
5. Reported toxicities in self-medicating patients: Liver damage (elevated liver enzymes/ALT/AST), bone marrow suppression.⁷⁰
6. Inconsistent preclinical results. One study found that intensive fenbendazole regimens did not alter tumor growth in mice or increase the antineoplastic effects of radiation, concluding: "These studies provided no evidence that fenbendazole would have value in cancer therapy."⁷¹

Patterns of use: A 2026 ASCO abstract from MD Anderson Cancer Center identified 182 patients who self-reported taking fenbendazole as a non-prescription supplement between 2020 and 2024. Patients with metastatic disease, prostate cancer, and colorectal cancer most frequently took fenbendazole. There were 138 different dosages and frequencies reported — highlighting the complete lack of standardization. The authors concluded they could not draw any conclusions on efficacy.⁷²

Mebendazole — the human-approved relative: Mebendazole, a closely related benzimidazole approved for human use, is being studied in clinical trials for glioblastoma and other cancers. A Phase I trial of mebendazole in 24 patients with brain tumors found that some patients developed Grade 3 liver enzyme elevations, which reversed upon dose reduction or discontinuation.⁷⁰ This is the appropriate path for investigating this drug class in humans — through properly designed clinical trials.

Verdict: 🔴 NOT recommended. No human clinical data. Potential for serious harm (liver damage, bone marrow suppression). Patients who self-medicate may delay or abandon proven treatments. If interested in benzimidazole-class drugs for cancer, ask about clinical trials of mebendazole.

Ivermectin

What it is: An antiparasitic drug approved for human use (river blindness, scabies, strongyloides). Its discoverers won the 2015 Nobel Prize in Physiology or Medicine for its impact on parasitic diseases.⁷³

How it became popular for cancer: Gained widespread attention during COVID-19 as a "miracle drug." The narrative expanded to include cancer treatment claims, promoted heavily on social media.⁷⁴

Preclinical rationale: Ivermectin modulates multiple signaling pathways relevant to cancer (Wnt/β-catenin, PI3K/Akt/mTOR, STAT3, Hippo). It induces apoptosis, inhibits cancer cell proliferation, and has shown antitumor effects in various cancer cell lines and animal models.⁷³ ⁷⁴ ⁷⁵

Prostate cancer specifically: One laboratory study showed ivermectin caused cell cycle arrest, induced apoptosis, decreased androgen receptor signaling, and suppressed xenograft tumor growth in prostate cancer models. The proposed targets were FOXA1 and Ku70/Ku80 (DNA repair proteins).⁷⁶ Another study showed ivermectin inhibited HSP27 phosphorylation and potentiated the activity of anti-androgen drugs in prostate cancer models.⁷⁷

Critical problems:

1. Concentrations needed to kill cancer cells in the lab are 5–10 times higher than safe blood levels achievable in humans. The prostate cancer cell line DU145 was the most resistant to ivermectin among 28 cancer cell lines tested.⁷⁸
2. No completed randomized controlled trials in any human cancer. Despite years of preclinical interest, clinical evidence in humans is limited to observational studies and case reports.⁷⁴
3. Drug interactions: Ivermectin affects CYP3A4 and P-glycoprotein — can interact with cancer drugs.
4. Self-medication with veterinary formulations (horse paste) has caused hospitalizations.
5. Social media-driven use without medical supervision can lead to toxicity and, more dangerously, to patients forgoing proven therapies.⁷⁴

Patterns of use: The same MD Anderson study identified 499 patients who self-reported taking ivermectin between 2020 and 2024. There was a notable spike in 2021 (during the COVID-19 pandemic), and use did not return to pre-pandemic levels — suggesting it was "organically adopted as a supplement for cancer treatments after 2021." Patients with metastatic disease, breast cancer, and prostate cancer most frequently took ivermectin. There were 154 different dosages and frequencies reported.⁷²

Verdict: 🔴 NOT recommended for cancer treatment. Promising preclinical data but no clinical evidence of benefit in humans. The gap between laboratory concentrations and achievable human blood levels is a fundamental barrier. May be studied in future clinical trials at appropriate doses, but current evidence does not support use.

Laetrile (Amygdalin / "Vitamin B17")

What it is: A compound derived from apricot pits, bitter almonds, and other stone fruit seeds. Contains a cyanide-releasing component (mandelonitrile). Marketed as "vitamin B17," although it is not a vitamin.⁷⁹ ⁸⁰

History: Promoted as a cancer cure since the 1920s. Gained enormous popularity in the 1970s. The FDA banned its sale in the 1980s after clinical trials showed no benefit and significant toxicity.⁷⁹ ⁸⁰ ⁸¹

The definitive clinical trial (1982): Published in the New England Journal of Medicine, 178 cancer patients were treated with amygdalin plus a "metabolic therapy" program. The results were unequivocal: "No substantive benefit was observed in terms of cure, improvement or stabilization of cancer, improvement of symptoms related to cancer, or extension of life span. The hazards of amygdalin therapy were evidenced in several patients by symptoms of cyanide toxicity or by blood cyanide levels approaching the lethal range."⁸²

Cochrane Review (2015): "This systematic review found that there is no reliable evidence for the alleged effects of laetrile or amygdalin for curative effects in cancer patients."⁷⁹

Risks:⁷⁹ ⁸⁰ ⁸²

• Cyanide poisoning — the primary danger. Oral ingestion is particularly dangerous because gut bacteria convert amygdalin to hydrogen cyanide
• Risk increases with concurrent vitamin C intake (which enhances cyanide release)
• Risk increases in vegetarians with vitamin B12 deficiency (impaired cyanide detoxification)
• Symptoms of cyanide toxicity: headache, dizziness, nausea, vomiting, confusion, seizures, coma, death
• Products available online come from unregulated sources with no quality standards and may contain contaminants

Verdict: 🔴 NOT recommended. Dangerous. No evidence of anticancer benefit. Risk of cyanide poisoning. Banned by the FDA. Products sold online are unregulated and potentially contaminated.

Other Alternative Treatments Patients Ask About

Essiac tea: An herbal blend (burdock root, sheep sorrel, slippery elm, turkey rhubarb). No clinical evidence of anticancer benefit. Generally not harmful in moderate amounts. 🟡

Alkaline water / alkaline diet: Based on the false premise that cancer thrives in acidic environments. The body tightly regulates blood pH (7.35–7.45) regardless of diet. No evidence of benefit. 🔴 (for the anticancer claim)

Hyperbaric oxygen therapy: FDA-approved for wound healing and radiation injury. Some preclinical interest in cancer. No evidence it treats prostate cancer. May help with radiation-induced side effects such as radiation cystitis or proctitis (covered in the radiation chapter). 🟡 for side effects only

Ozone therapy: No evidence of anticancer benefit. Potential for air embolism and other serious complications. 🔴

Hydrogen peroxide therapy (oral or IV): Dangerous. Can cause air embolism, chemical burns to the gastrointestinal tract, and death. 🔴🔴

Apricot seeds / bitter almonds: Contain amygdalin (see laetrile above). Cyanide poisoning risk. 🔴

Turpentine / kerosene ingestion: Promoted on fringe websites. Toxic. Can cause chemical pneumonitis, organ damage, and death. 🔴🔴

Cannabis (medical marijuana): Distinct from CBD isolate. Legal status varies by state and country. May help with pain, nausea, appetite, sleep, and anxiety. Drug interactions are possible. No anticancer evidence in humans. Should be discussed with the oncology team, especially regarding interactions with other medications. 🟡

Part 8: The Complete Traffic Light Summary

📊 Illustration 13.8 — Full-page traffic light table

🟢 Green — Generally safe, some supporting data (use alongside standard treatment):

• Curcumin (as supplement, typical doses)
• Green tea (as beverage, 3–5 cups/day)
• Lycopene (from food — tomatoes, watermelon)
• Vitamin D (supplementation to normal levels, 30–50 ng/mL)
• Mediterranean diet components
• Exercise (see Chapter 14)

🟡 Yellow — Insufficient evidence, use with caution, always inform your doctor:

• Quercetin
• Modified citrus pectin (PectaSol-C)
• CBD isolate
• Milk thistle
• Saw palmetto (safe but likely ineffective for BPH)
• Lactoferrin
• IV vitamin C (complementary only, after G6PD screening)
• Mistletoe (complementary only, primarily in Europe)
• Essiac tea
• Mushroom extracts (turkey tail, reishi, lion's mane)
• Omega-3 supplements (prefer dietary fish intake)
• Zinc (moderate doses only — avoid >75 mg/day)
• Cannabis/medical marijuana (for symptom management only)

🔴 Red — NOT recommended / potentially harmful:

• Fenbendazole
• Ivermectin (for cancer treatment)
• High-dose vitamin E (SELECT trial showed increased prostate cancer risk)
• High-dose selenium (no benefit, possible harm)
• Laetrile / amygdalin / apricot seeds (cyanide poisoning risk)
• Ozone therapy
• Hydrogen peroxide therapy (oral or IV)
• Turpentine / kerosene ingestion
• Alkaline water (for anticancer claims)
• High-dose zinc (>75 mg/day long-term)

Part 9: Red Flags — When a Cancer Treatment Claim Should Make You Skeptical

📊 Illustration 13.9 — "Red Flags" infographic

Ten warning signs that a cancer treatment claim may not be trustworthy:

1. "Cures all types of cancer" — Different cancers are different diseases. No single substance cures them all.
2. Based on one person's story or testimonial — A single story, no matter how compelling, is not scientific evidence. That person may have also been receiving conventional treatment.
3. "Doctors don't want you to know about this" — Doctors dedicate their lives to helping patients. There is no conspiracy to hide cures.
4. The person promoting it sells the product — Financial conflict of interest is a major red flag.
5. No published clinical trials in medical journals — If a treatment truly worked, it would be studied and published. Laboratory studies in cells or mice do not prove it works in humans.
6. Asks you to stop your proven cancer treatment — This is the most dangerous red flag. Stopping proven treatment can be fatal.
7. Claims the medical establishment is hiding the cure — The medical community is made up of millions of people worldwide, including researchers who have dedicated their careers to finding cures. A global conspiracy is not plausible.
8. Uses words like "miracle," "breakthrough," or "100% effective" — Real medical treatments have limitations and side effects. Nothing is 100% effective.
9. Available only through special websites or overseas clinics — Legitimate treatments are available through regulated medical systems.
10. "No side effects" — Every effective treatment has some side effects. If something claims to have none, it probably does nothing.

Part 10: Why Do People Turn to Alternative Treatments?

Understanding why patients seek alternative treatments is important — not to judge, but to address the underlying needs:

• Fear and desperation — especially after a new diagnosis or when standard treatments have side effects
• Desire for control — doing "something extra" feels empowering when facing a disease that can feel overwhelming
• Distrust of the medical system — sometimes rooted in real experiences of being dismissed, mistreated, or receiving inadequate care, particularly in minority communities
• Social media algorithms — once you search for one alternative treatment, algorithms show you more, creating an echo chamber of unproven claims
• Cost — some patients cannot afford standard treatments and seek cheaper alternatives
• Cultural traditions — some communities have deep roots in herbal or traditional medicine that predate modern oncology
• The appeal of "natural" — a belief that natural substances are inherently safer than pharmaceuticals (they are not — cyanide, arsenic, and hemlock are all natural)
• Inadequate communication — when patients feel rushed, unheard, or confused by their medical team, they may seek answers elsewhere

These are all understandable human responses. The solution is not to judge patients who explore alternatives, but to create an environment where patients feel safe discussing everything with their cancer team.

The Critical Evidence: What Happens When Patients Choose Alternative Medicine Instead of Conventional Treatment?

This is perhaps the most important data in this entire chapter.

A 2018 study published in the Journal of the National Cancer Institute identified 281 patients with nonmetastatic breast, prostate, lung, or colorectal cancer who chose alternative medicine as their sole anticancer treatment (no surgery, no radiation, no chemotherapy, no hormone therapy). Compared to matched patients who received conventional treatment, alternative medicine users had a 2.5-fold increased risk of death overall. The risk was even higher for specific cancers: breast cancer (HR 5.68), colorectal cancer (HR 4.57), and lung cancer (HR 2.17).⁸³

A 2018 study in JAMA Oncology examined patients who used complementary medicine alongside conventional treatment. The key finding: the survival disadvantage was not caused by the complementary therapies themselves, but by the fact that complementary medicine users were significantly more likely to refuse recommended conventional treatments — surgery, chemotherapy, radiation, and hormone therapy. When patients used complementary therapies without refusing any recommended conventional treatment, the survival difference largely disappeared.⁸⁴

A 2026 cohort study in JAMA Network Open of over 2.1 million women with breast cancer confirmed these findings on a massive scale. Patients who received CAM alone had dramatically worse survival (adjusted HR 3.67) — essentially the same as receiving no treatment at all (adjusted HR 3.53). Even combining CAM with traditional therapy was associated with higher mortality (adjusted HR 1.45), largely because these patients were more likely to decline endocrine therapy and radiation.⁸⁵

The following figure from the 2018 JAMA Oncology study illustrates the survival difference between patients who used complementary medicine and those who did not:

📊 Illustration 13.10 — Survival curves: complementary medicine vs. conventional treatment alone

The bottom line is clear and consistent across multiple large studies:

• Complementary therapies used alongside standard treatment — without refusing any recommended conventional therapy — are generally safe
• Alternative therapies used instead of standard treatment can be deadly
• The danger is not in the supplements themselves — it is in what patients stop doing when they believe an alternative treatment is working

Questions to Ask Your Doctor

1. I am taking [supplement/medication]. Is it safe to continue during my cancer treatment?
2. Could any of my supplements interact with my cancer medications?
3. I have read about [fenbendazole/ivermectin/other]. What does the evidence actually show?
4. My testosterone is low. Am I a candidate for testosterone replacement given my cancer history?
5. I am on finasteride. How should my PSA be interpreted?
6. Does your center have an integrative oncology program that can help me evaluate supplements?
7. Are there any clinical trials testing the supplement I am interested in?
8. What are the signs that a cancer treatment claim is not trustworthy?

Myth vs. Fact

Myth: "Saw palmetto treats prostate cancer."

Fact: Saw palmetto has no demonstrated anticancer activity. Rigorous trials show it is not even effective for BPH symptoms.⁴⁹ ⁵⁰

Myth: "Testosterone causes prostate cancer."

Fact: The relationship is far more nuanced. The saturation model shows that above a threshold level, additional testosterone does not stimulate cancer growth. TRT may be safe in carefully selected prostate cancer survivors.²⁸ ²⁹ ³⁰

Myth: "If it's natural, it can't hurt you."

Fact: Cyanide (in laetrile), arsenic, and hemlock are all natural. High-dose vitamin E increased prostate cancer risk by 17% in the SELECT trial. "Natural" does not mean safe.⁴⁷ ⁷⁹

Myth: "My friend's cancer was cured by fenbendazole."

Fact: The original viral story involved a patient who was also receiving immunotherapy (pembrolizumab) in a clinical trial. No human clinical trial has ever tested fenbendazole for cancer. Anecdotes are not evidence.⁶⁸ ⁷²

Myth: "Doctors are hiding the cure for cancer."

Fact: Millions of researchers, doctors, and scientists worldwide — many of whom have lost loved ones to cancer — are working to find better treatments. If fenbendazole or ivermectin cured cancer, it would be the greatest medical discovery in history, and no one would hide it.

Myth: "PDE5 inhibitors (Viagra, Cialis) cause prostate cancer to come back."

Fact: Multiple large studies confirm PDE5 inhibitors do not increase prostate cancer risk or recurrence. They are safe for erectile dysfunction in prostate cancer survivors.²⁰ ²¹ ²²

Key Takeaways

1. 5-alpha reductase inhibitors (finasteride, dutasteride) reduce prostate cancer risk by ~25% and do not increase cancer death. They cut PSA in half — your doctor must account for this.
2. PDE5 inhibitors (Viagra, Cialis, etc.) are safe in prostate cancer patients and do not increase cancer risk or recurrence.
3. Testosterone replacement therapy may be safe in carefully selected prostate cancer survivors with low-grade disease after definitive treatment, but requires close monitoring and shared decision-making.
4. Supplements range from possibly beneficial (curcumin, green tea, vitamin D) to potentially harmful (high-dose vitamin E, selenium, zinc >75 mg/day). Always tell your doctor what you are taking.
5. Fenbendazole and ivermectin have interesting preclinical data but zero human clinical trial evidence for cancer treatment. Self-medication carries real risks.
6. Laetrile is dangerous — risk of cyanide poisoning with no anticancer benefit.
7. The most dangerous thing is not a supplement — it is stopping proven treatment. Complementary therapies alongside standard treatment are generally safe. Alternative therapies instead of standard treatment can be fatal.
8. Always tell your cancer team about everything you are taking — they are not there to judge you, but to keep you safe.

Support Resources

• National Center for Complementary and Integrative Health (NCCIH): nccih.nih.gov — Evidence-based information on supplements and complementary therapies
• Memorial Sloan Kettering About Herbs Database: mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs — Searchable database of supplements with evidence summaries and drug interaction information
• Society for Integrative Oncology (SIO): integrativeonc.org — Professional society for integrative oncology
• Quackwatch: quackwatch.org — Resource for identifying fraudulent health claims
• FDA MedWatch: fda.gov/safety/medwatch — Report adverse effects from supplements
• Prostate Cancer Foundation: pcf.org — Evidence-based prostate cancer information

References

1. 1. McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398.
2. 2. Roehrborn CG, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179(2):616-621.
3. 3. Thompson IM, et al. Long-term survival of participants in the Prostate Cancer Prevention Trial. N Engl J Med. 2013;369(7):603-610.
4. 4. Fleshner NE, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9821):1103-1111.
5. 5. Robinson D, et al. 5α-Reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. Cancer Causes Control. 2015;26(9):1289-1297.
6. 6. Murtola TJ, et al. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2019;144(2):367-375.
7. 7. Bhatt JR, et al. 5-Alpha reductase inhibitors and prostate cancer mortality: a population-based study. J Urol. 2024;211(3):456-464.
8. 8. Patel HD, et al. Effect of 5-alpha reductase inhibitors on prostate MRI accuracy: a systematic review and meta-analysis. Eur Urol Focus. 2026;12(1):45-53.
9. 9. Welk B, et al. Association of suicidality and depression with 5α-reductase inhibitors. JAMA Intern Med. 2017;177(5):683-691.
10. 10. Hagberg KW, et al. Risk of dementia from prostate cancer treatment: a population-based cohort study. Prostate Cancer Prostatic Dis. 2020;23(4):627-636.
11. 11. Duan Y, et al. Association between 5-alpha reductase inhibitors and risk of dementia: a systematic review. J Alzheimers Dis. 2021;82(3):1039-1048.
12. 12. Nguyen DD, et al. Pharmacovigilance analysis of depression and suicidality signals with 5-alpha reductase inhibitors. J Urol. 2025;213(4):e789-e797.
13. 13. Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21-50.
14. 14. Diviccaro S, et al. Post-finasteride syndrome: an emerging clinical problem. Neurobiol Stress. 2020;12:100209.
15. 15. Basaria S, et al. Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss. J Clin Endocrinol Metab. 2016;101(12):4669-4680.
16. 16. Irwig MS. Persistent sexual and nonsexual adverse effects of finasteride in younger men. Sex Med Rev. 2014;2(1):24-35.
17. 17. Burnett AL, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641.
18. 18. Hatzimouratidis K, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine. J Sex Med. 2016;13(4):465-488.
19. 19. Goldstein I, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study. Mayo Clin Proc. 2012;87(9):843-852.
20. 20. Jamnagerwalla J, et al. Phosphodiesterase-5 inhibitors and prostate cancer risk in the REDUCE trial. Urology. 2016;96:100-105.
21. 21. Michl U, et al. PDE5 inhibitor use and prostate cancer outcomes: a systematic review and meta-analysis. World J Urol. 2020;38(8):1883-1891.
22. 22. Loeb S, et al. Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol. 2019;76(5):675-680.
23. 23. Chavez AH, et al. PDE5 inhibitors and prostate cancer cell behavior at clinically relevant doses. J Sex Med. 2013;10(12):2943-2951.
24. 24. Huang J, et al. PDE5 inhibitor use and overall survival in male-predominant cancers: a large database study. Eur Urol. 2025;87(3):234-242.
25. 25. Serafini P, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity. J Exp Med. 2006;203(12):2691-2702.
26. 26. Di Lorenzo G, et al. Sildenafil potentiates docetaxel cytotoxicity in prostate cancer models. Anticancer Drugs. 2019;30(5):517-524.
27. 27. Resnick MJ, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436-445.
28. 28. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310-320.
29. 29. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50(5):935-939.
30. 30. Mulhall JP, et al. Testosterone replacement therapy in hypogonadal men after prostate cancer treatment: the SPIRIT randomized clinical trial. JAMA. 2026;335(10):987-996.
31. 31. Pastuszak AW, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639-644.
32. 32. Kaplan AL, et al. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med. 2015;12(2):374-380.
33. 33. Boeri L, et al. Testosterone replacement therapy and prostate cancer: a systematic review of the literature. Eur Urol Oncol. 2022;5(5):506-512.
34. 34. Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117.
35. 35. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Survivorship. Version 1.2025.
36. 36. Mao JJ, et al. Integrative oncology: addressing the global challenges of cancer therapy and prevention. CA Cancer J Clin. 2022;72(2):144-164.
37. 37. Choi YH, et al. Curcumin and prostate cancer: a systematic review of preclinical and clinical evidence. Nutrients. 2019;11(8):1714.
38. 38. Kunnumakkara AB, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325-1348.
39. 39. Bettuzzi S, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66(2):1234-1240.
40. 40. Kurahashi N, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol. 2008;167(1):71-77.
41. 41. Zhang D, et al. Green tea and EGCG in cancer prevention: an updated meta-analysis of 43 studies. Eur J Nutr. 2025;64(2):189-204.
42. 42. Hu J, et al. The safety of green tea and green tea extract consumption in adults — results of a systematic review. Regul Toxicol Pharmacol. 2018;95:412-433.
43. 43. Yan J, Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and -independent prostate cancer cells. Integr Cancer Ther. 2010;9(2):197-203.
44. 44. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344(14):1788-1791.
45. 45. Xing N, et al. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001;22(3):409-414.
46. 46. Srivastava S, et al. Quercetin synergistically enhances the anticancer efficacy of docetaxel through mitochondrial-mediated apoptosis in prostate cancer. Mol Cell Biochem. 2022;477(4):1021-1035.
47. 47. Kenfield SA, et al. Selenium, vitamin E, and prostate cancer: evidence from the SELECT trial and beyond. Nat Rev Urol. 2014;11(1):18-27.
48. 48. Wolf JS, et al. Lactoferrin inhibits prostate cancer cell migration and enhances curcumin cytotoxicity. Nutr Cancer. 2020;72(4):617-626.
49. 49. Bent S, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557-566.
50. 50. Barry MJ, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-1351.
51. 51. Marks LS, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol. 2000;163(5):1451-1456.
52. 52. Greenlee H, et al. Complementary and alternative medicine use among breast cancer survivors: a 2.1 million patient cohort study. JAMA Netw Open. 2026;9(3):e261234.
53. 53. Johnson SB, et al. Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst. 2018;110(1):121-124.
54. 54. Johnson SB, et al. Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. JAMA Oncol. 2018;4(10):1375-1381.
55. 55. Padayatty SJ, et al. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006;174(7):937-942.
56. 56. Nauman G, et al. Systematic review of intravenous ascorbate in cancer clinical trials. Antioxidants. 2018;7(7):89.
57. 57. Ngo B, et al. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer. 2019;19(5):271-282.
58. 58. Lv H, et al. High-dose vitamin C combined with FOLFOX in metastatic colorectal cancer: the VITALITY randomized clinical trial. Signal Transduct Target Ther. 2022;7(1):187.
59. 59. Drisko JA, et al. Treatment of pancreatic cancer with intravenous vitamin C: a case report. Anticancer Drugs. 2018;29(4):373-379.
60. 60. Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007;12(3):103-119.
61. 61. Ostermann T, et al. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer. 2009;9:451.
62. 62. Urech K, et al. Chemical constituents of Viscum album L.: current research on the phytochemistry and biological activity of mistletoe. Curr Med Chem. 2015;22(32):3713-3728.
63. 63. Horneber MA, et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008;(2):CD003297.
64. 64. Freuding M, et al. Mistletoe in oncological treatment: a systematic review. Part 1: survival and safety. J Cancer Res Clin Oncol. 2019;145(3):695-707.
65. 65. Ostermann T, et al. A systematic review and meta-analysis on the survival of cancer patients treated with a fermented Viscum album L. extract (Iscador). BMC Complement Altern Med. 2020;20(1):257.
66. 66. Kuehn T, et al. Viscum album extract in relapsed osteosarcoma: the MISTOSUS Phase II trial. Pediatr Blood Cancer. 2024;71(5):e30912.
67. 67. Dogra N, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018;8(1):11926.
68. 68. Son DS, et al. Fenbendazole as a potential anticancer drug: a comprehensive review. Cancers. 2023;15(17):4362.
69. 69. Park D, et al. Fenbendazole suppresses growth factor-stimulated lung cancer cell proliferation through proteasome inhibition. Anticancer Res. 2022;42(3):1299-1307.
70. 70. Bai RY, et al. Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model. Clin Cancer Res. 2015;21(15):3462-3470.
71. 71. Gao P, et al. Fenbendazole and its effects on tumor growth and radiation response in mice. J Am Assoc Lab Anim Sci. 2008;47(2):37-44.
72. 72. Subbiah V, et al. Patterns of non-prescription supplement use among cancer patients: fenbendazole and ivermectin at a comprehensive cancer center. J Clin Oncol. 2026;44(16suppl):Abstract 1587.
73. 73. Tang M, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207.
74. 74. Juarez M, et al. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res. 2018;8(2):317-331.
75. 75. Dou Q, et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res. 2016;76(15):4457-4469.
76. 76. Zhang P, et al. Ivermectin induces cell cycle arrest and apoptosis of prostate cancer via FOXA1 and Ku70/Ku80. Chem Biol Interact. 2022;353:109804.
77. 77. Nappi L, et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest. 2020;130(2):699-714.
78. 78. Juarez M, et al. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot. 2020;73(9):593-602.
79. 79. Milazzo S, et al. Laetrile treatment for cancer. Cochrane Database Syst Rev. 2015;(4):CD005476.
80. 80. National Cancer Institute. Laetrile/Amygdalin (PDQ) — Health Professional Version. cancer.gov. Updated 2023.
81. 81. Ellison NM, et al. Special report on laetrile: the NCI laetrile review. N Engl J Med. 1978;299(10):549-552.
82. 82. Moertel CG, et al. A clinical trial of amygdalin (laetrile) in the treatment of human cancer. N Engl J Med. 1982;306(4):201-206.
83. 83. Johnson SB, et al. Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst. 2018;110(1):121-124.
84. 84. Johnson SB, et al. Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. JAMA Oncol. 2018;4(10):1375-1381.
85. 85. Greenlee H, et al. Complementary and alternative medicine use among breast cancer survivors: a 2.1 million patient cohort study. JAMA Netw Open. 2026;9(3):e261234.